Focused on the spectrum of food allergy research.

Our precision medicine focus allows for unique models of research analysis not otherwise available in standard clinical trials. We also focus our efforts on novel clinical companion diagnostics, food conditioning programs, food dosing mechanisms, and more to assure maximal efficiency of treatment and minimal side effects. We house a basic science laboratory where new mechanisms of molecular food allergy diagnostics are studied at the level of DNA, blood, gastrointestinal tract, and other important organ systems.

Precision medicine advances science and medical treatment in a complex yet effective approach of the “N=1”. The N of any study is the number of patients. With nearly 1,700 patients treated for severe food allergic disease, the N of our institute exceeds that of many worldwide. The beauty of precision medicine is we are able to take thousands of individuals and utilize each of their cases to unmask millions of data points in their system of “1”. This unique approach is advocated by the NIH, FDA and leading research centers across the globe. While complex and difficult in its statistical analysis, this class of research offers the greatest hope in analyzing the “personalized” medicine behind food allergy treatment.

Translational research is classically referred to as “from bench to bedside”. Each of our patients undergoes 300 or more diagnostic biomarker tests. This data is reflective of their immune system from the bone marrow to the gastrointestinal tract. We utilize this data to extrapolate novel findings and study them in the clinical food allergy world. This approach aids in creating the best diagnostics possible in food allergy. Additionally, the long-term follow-up of patients involving the standardization of biomarkers will be critical to the lifelong treatment outcomes of food allergy patients.

SoCal Food Allergy is home to basic science research focused on food allergic disease. Research at the level of DNA, RNA, immune cells, and more are critical to the development of newer treatments for food allergy. We are particularly focused on the development of newer biomarkers which can predict and reflect short-term molecular changes and long-term impact changes toward immune system tolerance. Such markers are currently not available. With the advent of such markers, patients undergoing immunotherapy can receive appropriate changes to treatment regimens to maximize molecular and clinical outcomes.

Randhawa I and Morphew T.  Diagnostic Associations Of Ara h8 and Ara h9 Components In Peanut-allergic Children. Annals of Allergy, Asthma and Immunology.  Volume 117, Number 5, Supplement 1.  P168.  Nov 2016. http://epo.epostersonline.net/acaai2016/node/1088

Chong-Wei Cui, Joseph Yusin, Inderpal Randhawa. A Non-atopic Child With Recurrent Respiratory Infections Successfully Treated With Mast Cell Therapy. Volume 117, Number 5, Supplement 1. P270. Nov 2016.

Shin HW, Barletta B, Yoonessi L, Meinardi S, Leu SY, Radom-Aizik S, Randhawa I, Nussbaum E, Blake DR, and Cooper DM. Quantification of Aerosol Hydrofluoroalkane HFA-134a Elimination in the Exhaled Human Breath Following Inhaled Corticosteroids Administration. Clin Transl Sci. 2015 Jul 8. 10.1111/cts.12305 https://www.ncbi.nlm.nih.gov/pubmed/26155923

Get In Touch With Us
contact
Help Us Transform Lives
donate